Cover Image
市場調查報告書

中國的透析市場:市場分析與發展預測

Research and Development Prospect of China Dialysis Market, 2014-2018

出版商 Huidian Research 商品編碼 270549
出版日期 內容資訊 英文 113 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
中國的透析市場:市場分析與發展預測 Research and Development Prospect of China Dialysis Market, 2014-2018
出版日期: 2014年09月23日 內容資訊: 英文 113 Pages
簡介

中國國內的透析中心數量在2013年終的現在達到3637件。此外,透析市場2013年並達到約144億人民幣的規模。其中血液透析機約為115億人民幣,腹膜透析約為29億人民幣的規模。市場大部分為外資型企業(歐洲·美國·日本等)支配,國內企業只特化於透析用管·透析液等技術水準低的產品專門。但該情形開始微有了改變,開始出現特化於高端產品,並正在擴大其市佔率的企業。由於中國以都市區為中心,正在發展透析據點的整備,國內透析產業不久即將迎向黃金期。

本報告提供中國的人工透析的市場相關分析,提供您目前產業結構·特徵,到現在為止的市場趨勢與今後5年份的預測,主要的外資·國內企業簡介(企業概要,產業實際成果,發展策略等),投資機會與風險等調查資料·考察,並將結果概述為以下內容。

第1章 透析市場概要

  • 定義
  • 分類
  • 發展歷史

第2章 全球透析市場

  • 慢性腎衰竭的罹患率
  • 透析產品市場
  • 透析治療市場

第3章 中國的透析市場現狀

  • 發展情形
  • 各產品領域的競爭環境
  • 政策環境
    • 重病保險計劃的階段性引進
    • 透析治療:現在優先處理,但今後看政策決定
    • 國家衛生計劃生育委員會(NHFPC)的血液透析機中心的管理法規·基本標準的獨立性相關公開草案:強調緩和打入市場·開放市場的必要性
    • 為求醫療制度改革發展的主要課題:社會資本投資·醫療機關成立積極化

第4章 市場各部門概要

  • 透析設備
    • 市場需求的擴大和進口劇增
    • 外資型企業的市場壟斷
    • 反傾銷操作帶來的市場開放國內企業·消除貿易虧損的可能性
  • 透析器(透析器)
    • 市場需求
    • 流通管道的擴張
    • 市場競爭現況
    • 主要的技術課題
  • 血液透析機液
    • 目前市場規模達到8億人民幣,預測將更進一步擴大
    • 國內企業控制市場,但市場集中度仍低
    • 生產據點位置最佳化的重要性
    • 附加價值低
  • 血液透析機用管
    • 進入障礙高--市場規模為12億人民幣
    • 國內企業已經佔有市場佔有率的一半,進口替代化持續發展
  • 腹膜透析液(PDS)
    • PDS被國家重要藥(修訂版)所指定--市場規模為29億人民幣
    • Baxter (Guangzhou)壟斷市場

第5章 民間透析產業的發展

  • 目前發展情形
    • 透析服務的供不應求
    • 國立醫院PDS服務的不足,帶來民間企業彌補差距的機會
    • 隨著國立醫院的規模擴大限制,社會資本投資機會的開放·擴大
  • 位於發展初期階段的產品獨立型透析服務中心
  • 民間透析產業的3種主要經營模式
    • 獨立型透析中心:患者數是最大的障礙
    • 雖是急速擴大的模式,但收益率低
    • 與醫院的協調型模式
    • 民營化·規模經濟性:今後發展的方向性
  • 波特的五力分析·分析

第6章 透析設備的進出口

  • 進口
  • 出口

第7章 主要外資廠商

  • Fresenius(德國)
  • DaVita(美國)
  • 日機裝(日本)
  • Baxter(美國)
  • 旭化成(日本)
  • B.Braun(德國)
  • NxStage(美國)

第8章 主要國內廠商

  • Shandong Weigao Group Medical Polymer Company Limited
  • Huaren Pharmaceutical Co., Ltd.
  • Boxlight
  • Kelun Pharmaceutical
  • Jihua Medical Apparatus and Instruments Co., Ltd.
  • Chongqing Shanwaishan Science & Technology Co., Ltd (SWS)
  • Shandong Xinhua Medical Instrument Co., Ltd?iSHINVA?j
  • Bain Medical Equipment Co., Ltd.
  • Jiangsu Lengthen Life Science and Technology Co., Ltd.
  • Guangzhou Koncen Biotechnology Co., Ltd.
  • Shandong Blue Sail Plastic & Rubber Co., Ltd. (Blue Sail)
  • Hebei Changshan Biochemical Pharmaceutical Co., Ltd.

第9章 投資分析及中國透析產業的建議

  • 發展前景
  • 投資機會
  • 產業專家的建議

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Based on the 2013 version, this update Report provides detailed analysis on Chinese government policies about dialysis industry and the relevant effect in recent three years, and conducts in-depth research about dialysis industry segmentations. Moreover, it analyzes Chinese private-owned hemodialysis services. In the aspect of enterprises, this update Report not only updates the latest information about the key enterprises listed in 2013 version, but also adds the information about some enterprises who intend to enter into this industry. This update Report reflects an overall development situation of China's dialysis industry and provides references for investors and entrepreneurs.

In China, hemodialysis treatment has gained a wide popularity. By the end of 2013, the number of dialysis centers has amounted to 3637, contributing a make scale of CNY 14.4 billion, in which, hemodialysis was CNY 11.5 billion, and peritoneal dialysis was CNY 2.9 billion.

Foreign enterprises, such as, Germany Fresenius, Japan Nikkiso and Asahi Kasei, have dominated China's dialysis market. Chinese enterprises mainly are engaged in the production of dialysis tubing or dialysate and other low technology content products. And few Chinese enterprises are specialized in manufacturing dialysis machines and dialyzers or other high end products. Now the situation improved a little, Chinese enterprise Weigao has led China's hemodialysis machines and dialyzers manufacture, and Chinese enterprise Huaren Pharma has led China's peritoneal dialysis industry.

By the end of May 2014, rural residence critical illness insurance program has already covered over 50% counties (cities and districts) in whole China. And in Shandong, Tianjin, Jilin, Gansu, and Qinghai, and some other cities and provinces, the critical illness insurance program is in full swing, and the provincial government has implemented the overall planning in each administrative region. Huidian Research believes that along with the gradual implementation of critical illness program in China, more and more ESRD (End Stage Renal Disease) patients will enjoy the insurance guarantee. Therefore, China's dialysis industry is entering into golden development stage.

Table of Contents

1. Overview of Dialysis Market

  • 1.1. Definition
  • 1.2. Classification
  • 1.3. Historical Development

2. Global Dialysis Market

  • 2.1. Morbidity of Chronic Renal Failure
  • 2.2. Dialysis Product Market
    • 2.2.1. General Situation of Global Dialysis Product Market
    • 2.2.2. Products Made in Europe, America, and Japan Take up the Lion's Share in Global Market
    • 2.2.3. Fresenius Becomes the Giant in Manufacturing Hemodialysis Products
    • 2.2.4. Baxter Becomes the Giant in Manufacturing Peritoneal Dialysis Products
  • 2.3. Dialysis Treatment Market
    • 2.3.1. Overview of Global Market
    • 2.3.2. Market Situations in America, Japan, and China

3. Current Status of China's Dialysis Market

  • 3.1. Development Status
  • 3.2. Competition Landscape of Product Segmentations
  • 3.3. Policy Environment
    • 3.3.1. Gradual Implementation of Critical Illness Insurance Program
    • 3.3.2. Dialysis treatment has the priority to enjoy more benefits in the current short term, while the situation in the long run is determined by Medical Insurance Policy
    • 3.3.3. Exposure Draft Regarding the Independence of the Management Regulations and Basic Standards of Hemodialysis Center issued by NHFPC (National Health and Family Planning Commission of China): with obvious intention to ease the industry access and the openness is appealing
    • 3.3.4. Key Tasks for Deepening the Reform of Health System in 2014: actively promote social capital to invest in and set up medical institutions

4. Overview of Industry Segmentations

  • 4.1. Dialysis Machines
    • 4.1.1. Booming Market Demand and the Soaring Import
    • 4.1.2. China's Dialysis Machine Market is under Foreign Monopoly
    • 4.1.3. Anti-dumping Investigation Helps China Get out of Trade Deficit
  • 4.2. Dialyzers
    • 4.2.1. Market Demand
    • 4.2.2. Distribution Channel Expansion
    • 4.2.3. Competition Landscape
    • 4.2.4. Major Technical Breakthroughs
  • 4.3. Hemodialysis Solutions
    • 4.3.1. Current Market Scale is About CNY 800 Million and Keeps Growing
    • 4.3.2. Chinese Manufactures Take the Upper Hand but with Low Market Concentration Ratio
    • 4.3.3. Layout of Factory Address is Essential
    • 4.3.4. Low Added Value
  • 4.4. Hemodialysis Tube
    • 4.4.1. High Barriers to Entry and Market Scale is about CNY 1.2 Billion
    • 4.4.2. Chinese Manufacturers Take Half of the Market and the Substitution for Imported Ones is Accelerating
  • 4.5. Peritoneal Dialysis Solution (PDS)
    • 4.5.1. PDS has been Listed in National Essential Medicine New Version and the Market Scale is about CNY 2.9 Billion
    • 4.5.2. Baxter (Guangzhou) Possesses a Predominant Market Share

5. Development of China's Private Dialysis Industry

  • 5.1. Current Status of Development
    • 5.1.1. Inadequate Supply of Dialysis Services
    • 5.1.2. Insufficient Momentum for State-owned Hospital Developing PDS to Bridge the Supply Gaps
    • 5.1.3. Limited Expansion for State-owned Hospital and Development Opportunity unleashed for Social Capital
  • 5.2. Independent Dialysis Service Center is in Early Development Stage
  • 5.3. Three Major Operation Models for Private Dialysis Industry
    • 5.3.1. Independent Dialysis Center -Customs are the Biggest Barrier
    • 5.3.2. Quick Expansion Model but Low Profits
    • 5.3.3. Hospital Cooperation Model
    • 5.3.4. Privatization and Economies of Scale are Future Development Directions
  • 5.4. Porter Five Forces Analysis

6. Import and Export of Dialysis Equipment

  • 6.1. Import
  • 6.2. Export

7. Key Foreign Manufacturers

  • 7.1. Fresenius (Germany)
    • 7.1.1. Company Profile
    • 7.1.2. Medical Department Development
    • 7.1.3. Business in China
    • 7.1.4. Outlook
  • 7.2. DaVita (America)
    • 7.2.1. Company Profile
    • 7.2.2. Profitability
    • 7.2.3. Development Experience
  • 7.3. Nikkiso (Japan)
    • 7.3.1. Company Profile
    • 7.3.2. Main Products
    • 7.3.3. Business Performance
    • 7.3.4. Future 5 Year Plan
  • 7.4. Baxter (the United States)
    • 7.4.1. Company Profile
    • 7.4.2. Business Performance
    • 7.4.3. Renal Dialysis Business
    • 7.4.4. Development in China
  • 7.5. Asahi Kasei (Japan)
    • 7.5.1. Company Profile
    • 7.5.2. Operation Status of Health Care Department
    • 7.5.3. Main Products
    • 7.5.4. Development in China
    • 7.5.5. Future Development Strategy
  • 7.6. B.Braun (Germany)
    • 7.6.1. Company Profile
    • 7.6.2. Operation Conditions
    • 7.6.3. Dialysis Department
    • 7.6.4. Import Business in China
  • 7.7. NxStage (America)
    • 7.7.1. Company Profile
    • 7.7.2. Operation Conditions
    • 7.7.3. Portable Hemodialysis Machine Business
    • 7.7.4. Hemodialysis Machine Consumptive Materials Business

8. Key Domestic Production Enterprises

  • 8.1. Shandong Weigao Group Medical Polymer Company Limited
    • 8.1.1. Company Profile
    • 8.1.2. Operation Conditions
    • 8.1.3. Distribution Channel Expansion
    • 8.1.4. Hemodialysis Business
    • 8.1.5. PDS Business
  • 8.2. Huaren Pharmaceutical Co., Ltd.
    • 8.2.1. Company Profile
    • 8.2.2. Operation Conditions
    • 8.2.3. PDS Business Development and Distribution Channel Construction
    • 8.2.4. Future Development Planning
  • 8.3. Boxlight
    • 8.3.1. Company Profile
    • 8.3.2. Operation Conditions
    • 8.3.3. Hemodialysis Business Development
  • 8.4. Kelun Pharmaceutical
    • 8.4.1. Company Profile
    • 8.4.2. Main Products 88
    • 8.4.3. Operation Conditions
    • 8.4.4. Peritoneal Dialysis Business
    • 8.4.5. Development Strategy
  • 8.5. Jihua Medical Apparatus and Instruments Co., Ltd.
    • 8.5.1. Company Profile
    • 8.5.2. Product Research and Development
    • 8.5.3. Hemodialysis Business
    • 8.5.4. SWOT Analysis
    • 8.5.5. Future Development Strategy
  • 8.6. Chongqing Shanwaishan Science & Technology Co., Ltd (SWS)
    • 8.6.1. Company Profile
    • 8.6.2. Operation Conditions
    • 8.6.3. Main Customs
    • 8.6.4. Future Development Goal
  • 8.7. Shandong Xinhua Medical Instrument Co., Ltd. (SHINVA)
    • 8.7.1. Company Profile
    • 8.7.2. Operation Conditions
    • 8.7.3. Dialysis Business Promotion Strategy
    • 8.7.4. Dialysis Business Development
  • 8.8. Bain Medical Equipment Co., Ltd.
    • 8.8.1. Company Profile
    • 8.8.2. Competitive Advantages
    • 8.8.3. Development Planning
  • 8.9. Jiangsu Lengthen Life Science and Technology Co., Ltd.
    • 8.9.1. Company Profile
    • 8.9.2. Business Performance
    • 8.9.3. Main Products
    • 8.9.4. Future Development Strategy
  • 8.10. Guangzhou Koncen Biotechnology Co., Ltd.
    • 8.10.1. Company Profile
    • 8.10.2. Business Performance
    • 8.10.3. Future Development Planning
  • 8.11. Shandong Blue Sail Plastic & Rubber Co., Ltd. (Blue Sail)
    • 8.11.1. Company Profile
    • 8.11.2. Build Dialysis Industry Chain and Actively Pursue Industrial Transformation
  • 8.12. Hebei Changshan Biochemical Pharmaceutical Co., Ltd.
    • 8.12.1. Company Profile
    • 8.12.2. Dialysis Business Development

9. Analysis and Suggestions of the Investment in China's Dialysis Industry

  • 9.1. Future Development Forecast
  • 9.2. Investment Opportunity
  • 9.3. Experts' Suggestions
Back to Top